#USA #Beltsville #iPSCs #REPROCELL #GMP Master Cell Bank

REPROCELL's Innovative GMP Master Cell Bank for Clinical iPSCs

REPROCELL (TYO: 4978) has recently announced the launch of its cutting-edge Good Manufacturing Practice (GMP) Master Cell Bank (MCB) specifically designed for human induced pluripotent stem cells (iPSCs). This significant advancement allows REPROCELL to offer a comprehensive solution that adheres to US FDA regulations from its facility located in Beltsville, Maryland.

The newly established GMP Master Cell Bank service provides an all-inclusive workflow that encompasses the entire clinical iPSC manufacturing process. This includes the creation of StemRNA™ clinical seed iPSCs alongside the StemEdit gene editing, all the way to the GMP-compliant expansion of Master Cell Banks. By consolidating these essential elements, REPROCELL is simplifying the pathway for developers of cell therapies, enabling them to accelerate their Investigational New Drug (IND) submissions while minimizing regulatory uncertainties and manufacturing challenges.

One of the key highlights of this offering is the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from ethically sourced donor material in the United States. This seed clone meets all necessary FDA, EMA, and PMDA standards and comes with an active FDA Drug Master File (DMF). The process utilized to expand this clone into a GMP Master Cell Bank employs FDA-compliant closed system protocols. This means that clinical researchers and biotechnology firms can access a readily available, clinically validated starting material that complies with US regulations.

Moreover, for customers seeking alignment with European markets, REPROCELL has arrangements with its partner Histocell, which provides MCB/WCB manufacturing services that operate under stringent European Medicines Agency (EMA) oversight and hold relevant certifications from the Spanish Agency for Medicines and Medical Devices (AEMPS).

Key Features of the Innovative iPSC Platform

• - Donor Selection and Consent: Sourcing of donors and assessment of eligibility are conducted in full compliance with FDA, EMA, and PMDA requirements, ensuring that all participating donors have provided their consent for therapeutic applications.
• - Advanced Reprogramming Technology: The proprietary RNA reprogramming technique is employed to produce StemRNA™ Clinical iPSC Seed Clones, following the highest FDA/EMA/PMDA standards.
• - Quality Assurance Protocols: Each StemRNA Clinical Seed Clone undergoes rigorous testing, including whole-genome sequencing (WGS) to assess genetic integrity and evaluate any oncogenic risks.
• - State-of-the-Art Gene Editing: The StemEdit gene editing service offered by REPROCELL is crafted for optimal precision, achieving high target efficiency while minimizing potential off-target interactions and immunogenic concerns.
• - Regulatory Compliance in Manufacturing: The GMP MCB manufacturing process aligns with FDA regulations, and the same applies for the EMA and PMDA certified operations.

Product Overview: StemRNA™ Clinical iPSC Seed Clone – LLF-34-F3

The StemRNA™ Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy female donor with type O+ blood, who has been fully consented for both clinical and therapeutic usage. This clone is particularly optimized for allogeneic applications due to its homozygosity at the HLA-A and HLA-DPA1 loci, enhancing its compatibility with diverse patient populations. Like all other offerings, this seed clone is supported by an active FDA DMF, while the MCB expansion processes utilize FDA-compliant measures that guarantee traceability to provide clinically suitable starting materials.

REPROCELL also caters to varied clinical requirements by providing different StemRNA™ Clinical iPSC Seed Clones aligned with distinct donor profiles.

Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc., emphasized the importance of this innovation by stating, "Our complete clinical iPSC workflow, which integrates donor screening, seed iPSC manufacturing, StemEdit gene editing, and GMP cell banking under one umbrella, enables a streamlined path for clinical program development. This integrated platform is crafted to expedite IND/CTA submissions while ensuring that quality, traceability, and global regulatory standards are upheld."

Company Background

REPROCELL is dedicated to providing integrated solutions in the realms of stem cell research, gene editing, and GMP manufacturing. The organization supports entities across the academic, biotechnological, and pharmaceutical landscapes, focusing on delivering reliable, regulation-ready starting materials alongside comprehensive services necessary for successful clinical translation.

Such innovations, including REPROCELL’s comprehensive manufacturing solutions, are supported by funding from organizations like the Maryland Stem Cell Research Fund (MSCRF), related to commercialization grants. For further details regarding the full suite of offerings available, visit the REPROCELL website.